Repligen Corporation Common Stock vs TJX Companies Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while TJX Companies Inc trades at $144.21 (market cap $155.64B). The key difference: TJX Companies Inc is far larger — about 14× Repligen Corporation Common Stock's market cap, and TJX Companies Inc pays a 1.36% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and TJX Companies Inc for 97 Days on average.
| RGEN | TJX | |
|---|---|---|
Market Cap | $11.14B | $155.64B |
Volume | 1,259,263 | 7,499,607 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $168.41 |
52-Week Low | $102.87 | $122.84 |
Typical Hold Time | 0 Days | 97 Days |
Enterprise Value | $11.02B | $163.95B |
Dividend Yield | — | 1.36% |
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TJX trades at $142.80, up 0.62% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $56.36B in 2025, with net income of $4.86B and a high ROE of 62.17%. The stock is near its pivot point of $141, with resistance at $143 and support at $139. Analysts are overwhelmingly positive, with an 84.9% buy rating and a consensus price target of $174.15.
Outlook remains positive due to consistent earnings outperformance and projected revenue growth to $62.4B in 2026. Risks include high valuation multiples (P/E 26.2) and competitive pressures in off-price retail. Upside potential is supported by Wall Street optimism and strong cash flow trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →